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1. Introduction 
In the last decade, great advances in RNA biology have been achieved. Micro- and short-
interfering RNAs were once thought to be degradation products of larger RNA molecules. 
With the knowledge of today we know that they represent independent classes of small 
noncoding (~ 20-30 nt) RNAs regulating various cellular processes across the eukaryotes. 
The first miRNA lin4 was discovered in the Nematode C. elegans in the year 1993, when Lee 
et al. [1] demonstrated that this transcript works as an endogenous regulator of genes that 
control developmental timing. Five years later Fire et al. [2] showed the ability of exogenous 
double stranded RNA to targeted posttranscriptional gene silencing, which recognizes each 
target by Watson-Crick base pairing. This scientific breakthrough was awarded with the 
novel price 2007.  
The RNA interference (RNAi) is a naturally happening catalytic process, offering the 
possibility to silence every pathological interesting gene which is defective expressed in a 
given disease. Thus it will give new approaches in the development and applications of 
siRNA-based therapeutics. 
Since cardiovascular diseases (CVDs) are the main cause of mortality and morbidity in the 
Western world this chapter will discuss possible applications of si- and miRNA-based 
therapeutics and delivery systems with special regard to atherosclerosis, ischemic heart-
disease and hypertension. 
2. Molecular mechanism of RNAi 
2.1 siRNA pathway 
SiRNAs are ~ 20-25 nt regulatory molecules that play a primitive role in the defence against 
any foreign nucleic acid molecule derived from viruses or tranposons to preserve genome 
integrity. This hypothesis is supported by a study that demonstrates the passive uptake of 
siRNAs trough a membrane receptor protein called Systemic RNA Interference – Defective 1 
(SID-1) [3]. 
RNAi is induced by linear, long perfectly complementary dsRNA which is directly 
introduced in the cytoplasm or is taken up by the environment [4]. First the dsRNA is 
processed by the RNase III-type endonuclease Dicer in 21-23 bp long siRNA duplexes that 
have 3´overhangs and 5`phosphates. In general Dicer posseses six domains including DExH 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
514 
Helicase, DUF283, PAZ, RNAse IIIa, RNAse IIIb and RNA Binding Domain (RBD). The PAZ 
domain (Piwi, Argonaute, Zwille) binds to the 3‘-nt overhangs of the cleaved RNA substrate 
while RBD recognizes duplex structures of RNA [5]. The next step is the incorporation of the 
duplex siRNAs into the nuclease-containing multiprotein complex RISC (RNA-induced 
silencing complex). The duplex is then unwound by the helicase activity (PAZ-domain) of 
the nuclease Ago2 which activates RISC. The unwinding process starts from the end of the 
siRNA with lower thermal energy. One strand called guide strand remains within the 
RISC, while the passenger strand is degraded by exonucleases [6]. The 5`end of the guide 
strand contains the seed region between the ribonucleotides at position 2-7 and are 
responsible for governing the RISC to its binding to target sequences [7]. Then the guide 
strand activates the RNase activity (PIWI domain) of Ago 2 which cleaves the 
complementary target mRNA. As result of these two unprotected mRNA ends are built, that 
are fast degraded by intracellular nucleases. This gene silencing by mRNA cleavage is an 
effective and catalytic process due to the fact that the activated RISC is freed after one round 
and is ready for further destruction of target mRNAs resulting in target repression [8] (See 
also Figure 1). 
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Fig. 1. Mechanism of RNA interference (RNAi) in mammalian systems 
2.2 miRNA pathway 
MiRNAs are ~22 nt long single-stranded RNAs with endogenous distinct that serve as 
regulators for proteins that repress gene expression [9]. Initially their precursors (pri-
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miRNAs) are transcribed by the RNA polymerase II as single-stranded transcript that 
contain a local hairpin structure and also possess 5`cap and poly-A tail [10]. Secondly the 
pri-miRNAs are processed by the Drosha/Pasha complex (RNAse III) and they are excised 
as stem-loops (pre-miRNAs). Some pri-miRNAs are originated from introns and are called 
mitrons. They are generated by the pre-miRNA splicing machinery rather than by Drosha 
[11]. The pre-miRNA are then transported out of the nucleus in the cytoplasm and this 
transport is mediated by Exportin 5 and Ran-GTPase [12]. Subsequently the pre-miRNA is 
processed and shortened by Dicer to generate imperfectly-matched ds miRNA. Then the 
duplex miRNA is loaded on the Ago2-RISC complex and in case of imperfect sequence 
complementary the passenger strand is unwound by Ago2 producing a mature miRNA  that 
is bound to active RISC. 
The repression of the mature miRNA to genetic processes is made on two different levels: it 
recognizes and binds the 3`UTR of target mRNAs blocking translation or this binding 
results in mRNA degradation in special processing bodies, termed p-bodies [13, 14] (See also 
Figure 1).  
3. Delivery systems and designs of siRNA- and miRNA-based therapeutics 
According to its large molecular weight (~13 kDa) and high content of anionic charge (~40 
negative phosphate charge), unmodified naked siRNA does not freely enter cell membranes. 
Therefore delivery systems are needed to give an access for the nucleic acids to its 
intracellular sites of actions since all other contributing parts of the RNAi based machinery 
are provided by the target cell / target tissue [39, 75]. Another critical hurdle to overcome is 
the low biological stability of nucleic acids under physiological conditions, which is the 
topic of the following passage. 
3.1 Chemical modifications of siRNA: improving biological stability 
Both single-stranded nucleic acids and double-stranded nucleic acids are relatively fast 
degraded trough nuclease attack if they are applied in unmodified and naked form. These 
finding indicates that they have short half-lives in blood and serum in vivo because of the 
activity of endo-and exonucleases [15]. To avoid the rapidly degradation there have been 
made efforts in the chemical modifications of siRNAs including strategies that improve 
the cellular uptake due to the conjugation with cholesterol, peptides, aptamers or 
antibodies. 
These chemical modifications mainly focus on the backbone, base or sugar of the RNA. One 
strategy is to modify the 2`-position of the ribose enhancing duplex stability (Tm) and 
nuclease resistance of the phosphodiester bond between the nucleotides against hydrolysis. 
The 2`O-Methyl-modification (2`OMe) is a naturally found RNA which is untoxic but can 
implement the potency of the siRNA. To undergo this effect an alternation of  2`OMe with 
RNA or other 2`modifications can be used so that siRNA function and nuclease stability is 
preserved [16,17]. Another well studied 2`modification is the 2`fluoro (2`-F) modification 
at pyrimidine positions which show compliance with the siRNA potency and stabilisation 
of the duplex against nuclease degradation in vitro [18] and in vivo [19]. Morrissey et al 
[20] demonstrated that a combination of 2`OMe purines with 2`-F pyrimidines can 
generate RNA duplexes that are highly stable in serum and have good in vivo 
performance. The modification of internucleotide phosphate linkage through the 
replacement of the non-bridging oxygen with sulfur is also an efficient approach to 
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improve nuclease stability without reducing the potency of siRNA. This was revealed 
through several studies [21-23]. 
Furthermore the covalent conjugation of siRNA with various chemical groups can direct cell 
uptake and alter biodistribution. The attachment of hydrophobic ligands like chosterol is a 
prominent example to extend serum lifetime. Soutschek et al. demonstrated in a mice model 
that i.v. administration of anti-ApoB siRNA that contained two 2`OMe RNA residues, 
phosphorthioate 3`-end modification and a cholesterol group resulted in silencing of the 
apolipoprotein B gene and reduced total cholesterol and plasma levels of apoB protein [24]. 
These data suggest that chemical modifications are a useful tool to improve stability and 
cellular uptake of siRNAs in general. 
3.2 Off-targets: activation of the innate immune system 
In the design and selection of a siRNA sequence their effect on innate immune system has 
also to be considered. It have been shown that the introduction of too long ds RNA 
molecules (>30 nt) can initiate an antiviral IFN-response of the cell or can activate a cellular 
pathway that involves the serin/threonine protein kinase PKR [25, 26]. A suppression of 
these effects could be the use of smaller (21-23 nt) siRNAs and additional in vitro tests or 
BLAST search of desired siRNA sequences to avoid further immune responses. SiRNAs 
have also the potential to interfere with the innate immune system due to the activation of 
Toll-like receptors (TLRs). Especially TLR 3, 7 and 8 are expressed in endosomal 
compartments and exposure to these receptors is affected by strength of the entry of 
synthetic RNA enters the cell. TLR 3 recognizes motifs in ssRNA and TLR 7 and 8 notice 
motifs in dsRNA. TLR 7 is binding favourable to GU-rich sequences and selecting of 
sequences that are not recognized by this receptor will help to solve this problem [13]. 
Moreover it has been demonstrated that the use of chemical modification like 2`OMe can 
prevent the detection of siRNAs by the immune system. The study of Judge et al. showed 
that incorporation of two or three 2`OMe residues in a siRNA duplex can be enough to 
evade immune detection [27]. Another category of off-targets are the cross-reactions between 
the si- and mi-RNA-pathway. If one of the siRNA strands have partly complementary regions 
with the 3`UTR of not targeted mRNA it can result in imperfect base-pairing of guide strand 
and “target” strand. This will end in translational repression or exonucleolytic degradation in 
a way similar like miRNA silencing [28]. This mismatch effect would be avoided if the seed-
region of the guide strand between the 2 and 8 nucleotid position (5`end) is fully 
complementary with the target mRNA sequence. Thus homology screenings of seed regions of 
siRNA in the 3`UTR of all interfering and target genes would be useful [29]. 
3.3 In vivo delivery systems    
Beyond the importance of effective design of siRNA to achieve specific and potent target 
gene silencing, the therapeutic use of siRNA need reliable delivery into tissues and target 
cells. Due to the fact that small RNA molecules like si- and miRNA have a strong anionic 
charge of their backbone consisting of phosphodiesters and they have a considerable 
molecular weight it is not possible that they can simply enter the cell membrane by passive 
diffusion. This lead to the development of two main methods of delivery including viral and 
nonviral strategies, which have been already successfully applied in vitro and in vivo. 
Although viral transfection in patients is regarded very critically, the next paragraph should 
give a small overview of this technique. 
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Viral delivery sytems Nonviral delivery systems 
• Viral vectors: 
• Adenovirus, adenovirus-
associated virus, retrovirus (e.g. 
lentivirus) 
• Systemic delivery in vivo:                               
cationic delivery systems (e.g. PEI, 
Acetocollagen, Chitosan)                             
cationic liposomal delivery systems (e.g. in 
vitro: Lipofectamin, e.g. in vivo: SNALPs) 
 
• Local delivery strategies in vivo 
Table 1. Overview of following discussed delivery systems 
3.3.1 Viral delivery systems 
Viral vectors commonly consists of nucleic acids (shRNAs or miRNA mimics) that are 
incorporated in the backbone of the virus genome and are induced through a Pol II or Pol III 
promoter. They are surrounded by a viral capsid of proteins that usually interact with ECM-
molecules to enter the cell by membrane fusion or receptor binding [31]. The gene transfer 
with viral vectors is a highly effective method because only one application is able to silence 
the target gene for a long time in vivo [32]. But despite the great potency of viral vectors for 
delivery, one has to consider that threats like host immune responses, potential oncogen and 
mutagen properties can occur. The common used viral vectors are adenovirus, adenovirus-
associated virus (AAV) and retrovirus [31]. Especially lentiviral vectors, a class of 
retroviruses show great potential of infecting a wide variety of non-dividing and dividing 
cells, stable integration in host genome, and results in long term expression of the transgene 
[32]. This kind of vector are of great interest for the injection in non-dividing cells like 
neurons and are suitable in the therapy of brain specific diseases or expression of shRNAs 
targeting disease associated genes [33, 34]. A possible target of shsiRNA could be in the case 
of a neurodegenerative disease like alzheimer, the ┛-secretase BACE 1 which generates the 
toxic amyloid ß-peptid. This was demonstrated in a Alzheimer mouse model with reduction 
of endogenous levels of BACE1 by the use of a lentiviral vector expressing shRNA [35]. 
Adenoviral vectors have also been used for delivery of a shRNA in the brain directed 
against the mRNA expressing the polyQ-harbouring SCA-1 encoding transcript of 
spinocerebellar ataxia type 1 [36].  
Another field of treatment would be chronic viral infections like chronic hepapitis b that 
need long-term treatment. Kim et al. demonstrated the in vitro lentivirus-mediated delivery 
of shRNA against HBx can effectively suppress the replication of HBV and reduce HBV 
covalently closed circular DNA [37]. Nevertheless, the safety issue remains a parameter in 
the decision in the use of a viral vector. 
3.3.2 Nonviral delivery systems 
There have been made many investigations for the use of nonviral delivery systems, 
including formulations like cationic polymers, cationic lipids, antibodies, conjugates or 
naked siRNA. The first consideration of the choice of a delivery strategy must be if a local or 
systemic administration is needed for the intended disease target.  
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Systemic delivery strategies in vivo 
Cationic delivery systems 
All cationic vectors share the ability to form complexes with the polyanionic nucleic acids 
through electrostatic interactions. Another possibility is the formation of nanoparticles in 
which the nucleic acid is entrapped within the particle through ionic interactions. The 
advantage of these formulations is that the siRNAs are not reachable for nucleases until it 
reaches its destination through vesicular transport (endocytosis and/ or macropinocytosis). 
Nanoparticles and complexes must have a limited size of 100 nm to be taken up by cells and 
to suppress renal excretion [38]. 
Cationic polymer delivery systems of siRNA 
Cationic polymers that have been applied include both natural (e.g., acetocollagen, chitosan) 
and synthetic (e.g, polyethylenimine). Polyetylenimine (PEI) is one of the best investigated 
polymers for nucleic acid delivery [39].  
The polymer is linear or branched and has high cationic charge density.  
The PEI-siRNA complexes are endocytosed in the cell through electrostatic interactions 
where it escapes the endosome through the “proton-sponge-effect”. 
PEI has the ability to accept protons which results in a buffering-effect in the vesicular 
system and a subsequent influx of Cl- and water leading to a osmotic release of the 
complexes in the cytoplasm [40]. PEI is available in different weights, but low-molecular PEI 
is favourable because high molecular weight is highly toxic [41]. The linear 22kDa jetPEI 
was successfully used in a antiviral therapy of guinea pigs against a lethal Ebola virus [42]. 
PEI-siRNA complexes have also been effective applied as a antiviral agent in a murine 
model of influenza infection [43]. PEI-siRNA complexes have also been efficient targeted 
against many proteins like HER2 [44], VEGF [45] and many more [39].  
Acetocollagen is a natural polymer which is produced through pepsin treatment of type I 
collagen of calf dermis [46]. Acetocollagen/siRNA-mediated targeting have been 
demonstrated in the treatment of prostata and pancreatic cancer as well as virus replication 
[47, 48, 49]. Another well-tolerated natural polymer is chitosan that builds cationic 
complexes with siRNAs. Howard et al. showed effective RNAi delivery in epithelial cells in 
the lung of mice through the intrasal application of transgenic enhanced green fluorescent 
protein (EGFP) [50].  
Cationic liposomal delivery systems 
Cationic liposomes and lipoplexes have been successfully applied for in vitro and in vivo 
delivery of siRNA. Liposomes are vesicels that can improve drug delivery through their 
fusion with cell membranes and they consist of a soluable compartment enclosed in a 
bilayer of phosholipids in which polar drugs can be entrapped. Lipoplexes are particles that 
are built through a complex formation of nucleic acids and lipids. The advantage of lipid 
formulations is the increase of siRNA stability in serum and the protection to overcome 
renal excretion, but unfortunately cationic liposomes can interfere with proteins like 
lipoproteins or serum proteins which can result in off effects as aggregation. For in vitro use 
there are many commercial available formulations like Oligofectamine, Lipofectamine 
(Invitrogen), RNAifect (Qiagen). An example of liposomes is SNALP (stable nucleic acid 
lipid particles) that have been efficient used in the in vivo silencing of the apoB gene in mice 
and primates [51]. The silencing effect of only one intravenous dose of 2.5 mg per kg 
SNALP-formulated siRNA lasted for 11 days and showed a reduction of 90% of the apoB 
mRNA. 
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Local delivery strategies in vivo 
Especially the local application of siRNA at site-specific delivery targets offers the possibility 
to reduce the doses of use as well as preventing the threat of systemic off targets. 
Intraocular delivery 
Up to now it is possible to treat wet-age related macular degeneration (AMD) with si-RNA 
based therapeutics. This disease affects blood vessels behind the retina that show a 
overgrowth which can cause a loss of vision. A human clinical study with complete status 
show the potency of VEGF-targeted siRNA Bevasiranib (Acuity Pharmaceuticals) to reduce 
neovascularisation and is also thought for the treatment of diabetic macular oedema (clinical 
status: complete). A mouse model in which Bevasiranib (Cand 5) was used also showed 
downregulation of VEGF after ocular injection [52]. The Drug Ranibizumap (Sirna-
027/AGN211745) which was developed by the Merck-Sirna Therapeutics is also already 
under complete status in the treatment of AMD.  Another siRNA called RTP-801i from 
Silence Therapeutics is also under clinical investigation for AMD and renal injury use.  
Intratumoral delivery 
Calando Pharmaceuticals has induced a now active (not recruiting) status of a clinical trial 
in which the siRNA CALLAA-01 is encapsulated in the polymer cyclodextrin to built 
particles that are linked with transferrin. This siRNA is directed against a subunit of the 
ribonucleotide reductase to stop the synthesis of DNA required for growth within solid 
tumors. This is the first clinical attempt of connecting a siRNA particle with a receptor that 
is highly expressed on cancer cells, like transferrin to facilitate the uptake. Another example 
is the Atu-027 siRNA (Silence Therapeutics) which is thought to be effective in the treatment 
of gastrointestinal cancer that has achieved the status recruiting. 
Intranasal delivery 
Intranasal application of formulated siRNA is resulting in effective gene silencing in the 
lung. This has great benefit in the treatment of pulmonary diseases. 
Alnylam Pharmaceuticals have developed the first antiviral siRNA ALN-RSV01 which is 
directed against the respiratory syntical virus through the silencing of the nucleocapsid N-
gene of the virus [75].  
Other clinical trials are summed up in the following table  
 
siRNA/ miRNA Disease Clinical Status 
TD101 Pachyonychia congenita Completed 
PRO-040201 Hypercholesterolemia Recruiting 
Anti-miRNA SPC3649 Chronic Hepatitis C Recruiting 
Table 2. Clinical trials (a selection)  
4. Therapeutical applications of si- and miRNAs with focus on CVDs 
The treatment of CVDs with si- and mi-RNA based therapeutics is a very novel strategy 
with high potential for clinical applications. 
4.1 Possible targets of atherosclerosis therapy 
Atherosclerosis is a chronic, multifactorial, smoldering inflammatory disease of medium 
sized and large conductive arteries characterized by lipid-fuelled lesions. The major players 
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in the development of the disease are endothelial cells, monocytes, leukocytes and intimal 
smooth muscle cells [53]. Atherosclerotic lesions start to develop under an intact but 
activated, dysfunctional and partly leaky endothelium. Through the sites of defective 
endothelium especially lipoprotein particles can accumulate in the vessel wall where they 
can undergo modifications like oxidations. OxLDL is highly proatherogenic and is 
generated by myeloperoxidase, 15-lipoxygenase (or 12/15-LO), and/ or nitric oxide 
synthase (NOS) [53]. Especially the 12-15-LO is associated with cellular growth, migration, 
adhesion, and inflammatory gene expression in monocytes/macrophages, endothelial cells 
and vascular smooth muscle cells (VSMC). Li et al. demonstrated that shRNA was able to 
knockdown 12/15-LO in mouse macrophages and also in rat and mouse VSMCs. The 
knockdown of 12/15-LO had also functional effects which was showed through reduced 
monocyte-chemoattractant protein-1 (MCP-1) expression in a differentiated mouse 
monocyte line as well as reduced cellular adhesion and fibronectin expression in VSMCs 
[54]. Making 12/15-LO an interesting target of atherosclerotic RNAi based prevention. 
Endothelium is activated through atherogenic stimuli like oxLDL and cytokines, that 
induces expression of adhesion molecules like VCAM-1, ICAM-1 and selectins like P- and E-
selectin which have proven to be important in atherosclerotic lesion development [55, 56, 
57]. These adhesion molecules can contribute to the recruitment of monocytes as well as 
leukocytes and VSMCS. During the development of atherosclerosis and neointimal 
hyperplasia a transformation of VSMCs in the media from a contractile into a synthetic 
phenotype is ongoing and after the arrival of VSMCs in the intima of the arterial wall they 
begin to generate extracellular matrix, resulting in the formation of intimal lesions. Petersen 
et al. isolated VSMCs from the aorta of C57BL/6 mice and transfected them with siRNA 
targeting VCAM-1. In a migration assay they revealed that with the treatment of VCAM-1 
siRNA the number of migrated VSMCs was significant reduced [58]. These findings indicate 
that VCAM-1 is necessary for the migration of VSMCs in the intima and VCAM-1 siRNA 
expression is an eventually potent approach to prevent and treat atherosclerosis and 
restenosis. Another possible target of atherosclerotic therapy is the inhibition of leukocyte 
entry to lesion areas to stop inflammatory progression. Pluvinet et al demonstrated that 
efficient blockage of the CD40-CD154 signaling by RNAi-mediated silencing of human 
CD40 expression on vascular endothelial cells leads to inhibition of VCAM-1, ICAM-1 and 
E-selectin expression and to a concomitant reduction of leukocyte adherence on these cells 
[59]. This signalling way is very interesting because the CD40-CD154 interaction also 
triggers matrix metalloproteinase (MMP) expression and these enzymes destabilize lipid-
rich core of plaques which can cause thrombosis. SMCs are also responsible for the fibrin 
cap production which contributes also to neointimal thickening after arterial injury which 
can lead to restenosis. The discoidin domain receptor 2 (DDR2) plays potential roles in the 
regulation of collagen turnover mediated by VSMCs in atherosclerosis. DDR 1 and DDR 2 
are nonintegrin receptors of collagen [60]. Shyu et al applied in a balloon injured rat model 
the DDR2 siRNA for attenuating the neointimal formation and decreasing the MMP2 
protein labeling in vitro and in vivo [61]. Another study also showed successful in vivo 
transplantation of coated stents with a cationized pullulan-based hydrogel loaded with 
MMP2 siRNA. San Juan et al demonstrated in this study an uptake of siRNA into the 
arterial wall and a decrease of pro-MMP2 activity [62]. This stent coating technology could 
be a auspicious therapeutic approach for prevention of restenosis. 
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4.2 Possible targets of hypertension therapy 
Hypertension also represents a severe riskfactor for many chronic CVDs. The use of cationic 
liposomal gene delivery vectors like DOTAP could be one possible strategy to reduce blood 
pressure. This finding was recently confirmed by Arnold et al., who showed that a single 
dose of 1mg/kg i.v. of siRNA-DOTAP (N-[1-(2,3-dioleoyloxy)]-N-N-N trimethyl 
ammonium propane) lipoplexes lead to the selective inhibition of ┚1-adrenoreceptor 
expression and reduced blood pressure lasting for 12 days [63]. The reduced blood pressure 
was also not greater if the ┚1-adrenoreceptor were blocked by ┚-blockers.  
Sun et al. also used RNAi to inhibit ┙1D-adrenerig receptor gene in rat VSMCs and the 
therapeutic implications of this treatment are of great interest, for the reason that 
pharmacologic blockage of ┙1-ARs is a commonly used treatment for hypertension [64]. A 
other area of gene targeting in hypertension are the blockage of receptors that are affected 
by potent vasoconstrictors like Angiotensin II (Ang II). Ang II exerts its physiological effects 
by activating multiple subtypes of its receptor such as AT1a-, AT1-b and AT2-receptors. It 
regulates diverse functions of the cardiovascular system as increases in blood pressure, 
extracellular fluid volume, hormone secretion, stimulation of sympathetic nerve activity, 
damping of baroreflexes and vascular and cardiac remodelling [65, 66]. Mostly the effects 
are mediated through AT1R. Vázquez et al. used AT1147siRNA to silence the AT1a receptor 
for up to 7 days, with decrease of Ang II binding to cells that were transfected [67]. Thus this 
target will be an interesting field in CVD therapy. 
4.3 Possible targets of ischemic heart-disease (IHD) therapy 
The therapeutic opportunities for the treatment of IHD range from medical therapy 
achieving to decrease myocardial oxygen consumption and increase coronary flow to 
revascularization. Revascularization is done through coronary artery bypass grafting 
(CABG) or percutaneous coronary angioplasty (PCI) in most cases with stent positioning 
[68].  
Through hypoxia the hypoxia inducible factor-1 transcriptional factor (HIF1-TF) can activate 
several angiogenic genes. HIF1-TF is naturally degraded by prolyl hydroxylase-2 (PHD2). 
Huang et al. imaged the biological role of shRNA therapy for improving cardiac function. 
Inhibition of PH2D by shRNA led to significant improvement in angiogenesis and 
contractility by in vivo and in vitro experiments and this process can be followed by 
molecular imaging [69]. Markkanen et al. reviews also that combined use of growth-factors 
or of factors that are capable of up-regulating other factors (e.g. HIF-1) will improve 
collateral vessel growth in case of IHD [70]. The potential use of miRNAs could also be a 
strategy for IHD treatment. MiRNAs contribute in the regulation of angiogenesis. Especially 
miR-126 can regulate angiogenesis and vascular integrity due to two recent studies [71, 72]. 
MiR-126 was demonstrated to be one of the most expressed miRNAs in cardiovascular 
tissue. Wang et al. generated miR-126 null mice that showed decreased sprouting potential 
of endothelial cells in vitro and also defective response to angiogenic factors in vivo [72]. 
These mice also showed decreased vascularization of infarcted myocardium, stronger 
fibrosis and loss of functional myocardium and were more prone to cardiac rupture. The 
search of mir-126 targets identified Spred-1, which is an negative regulator of the MAP 
kinase pathway that signals the pathway of angiogenic regulators like VEGF [68].   
Thus an upregulation of miR-126 could be effective in the repression of antiangiogenesis. 
Another study by Fasanaro et al. also revealed a hypoxia induced upregulation of miR-210 
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in endothelial cells [73]. They used endothelial cells that were cultured under oxygen 
deprivation, which were derived from human, umbilical veins. It was shown that the 
overexpression of miR-210 stimulated angiogenesis in mormoxic endothelial cells, while 
miR-210 blockage inhibited it [73, 68]. A target of miR-210 is Ephrin-A3 which is a regulator 
of angiogenesis and VEGF signaling. 
5. Conclusions and future perspectives 
Since CVDs are the leading cause of morbidity and mortality in the world, siRNA and 
miRNA-based therapeutics represent a new approach to treat CVDs. Due to the fact, that 
RNAi technology has shown a fast development from the research level to human clinical 
trials as an effective gene-silencing method since its discovery in 1998, it shows great 
advantages for use in routine clinical practice as an adjuvance of existing therapies. The 
challenging hurdle remains the delivery of nucleic acids in vivo including the improvement 
of biological properties such as delivery efficacy, cellular uptake and well pharmacokinetics 
to achieve drug release to the wished target cell type. But there have been already made 
great efforts in the establishment of siRNA delivery methods like cationic polymer-mediated 
siRNA delivery, targeted siRNA delivery and conjugation or chemical modifications of 
siRNAs. Thus on going research and pratical use will improve the safety issue in general 
making RNAi-based therapeutics a new class of drugs with high potential, especially in the 
treatment of a wide field of diseases. 
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